Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8687501 | NeuroImage: Clinical | 2018 | 10 Pages |
Abstract
Antiangiogenic therapy is a universal approach to the treatment of malignant gliomas but fails to prolong the overall survival of newly diagnosed or recurrent glioblastoma patients. Imaging biomarkers are quantitative imaging parameters capable of objectively describing biological processes, pathological changes and treatment responses in some situations and have been utilized for outcome predictions of malignant gliomas in anti-angiogenic therapy. Advanced magnetic resonance imaging techniques (including perfusion-weighted imaging and diffusion-weighted imaging), positron emission computed tomography and magnetic resonance spectroscopy are imaging techniques that can be used to acquire imaging biomarkers, including the relative cerebral blood volume (rCBV), Ktrans, and the apparent diffusion coefficient (ADC). Imaging indicators for a better prognosis when treating malignant gliomas with antiangiogenic therapy include the following: a lower pre- or post-treatment rCBV, less change in rCBV during treatment, a lower pre-treatment Ktrans, a higher vascular normalization index during treatment, less change in arterio-venous overlap during treatment, lower pre-treatment ADC values for the lower peak, smaller ADC volume changes during treatment, and metabolic changes in glucose and phenylalanine. The investigation and utilization of these imaging markers may confront challenges, but may also promote further development of anti-angiogenic therapy. Despite considerable evidence, future prospective studies are critically needed to consolidate the current data and identify novel biomarkers.
Keywords
KtransCBVrCBF18F-FDOPAFDG18F-FLTVEGF-APWIDWIGBMCBFMRSRSIDCE-MRIfluorodeoxyglucosed-2HGFDMSVNIROIrelative cerebral blood flowADCrCBVTMZDSC-MRIDynamic susceptibility contrast magnetic resonance imagingPFsAnti-angiogenicFLAIRMRIfluid-attenuated inversion recoveryprogression-free survivaloverall survivalImagingPerfusion-weighted imagingdiffusion-weighted imagingMagnetic resonance imagingDynamic contrast-enhanced magnetic resonance imagingTemozolomidePositron emission computed tomographycomputed tomographycerebral blood flowCerebral blood volumeRelative cerebral blood volumeTherapyCNSBBBblood brain barriercentral nervous systemRANOapparent diffusion coefficientmagnetic resonance spectroscopyVascular endothelial growth factor ASUVstandardized uptake valueregion of interestBiomarkersPETGlioblastomaRecurrent glioblastomaGliomaVAI
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
Ziren Kong, Chengrui Yan, Ruizhe Zhu, Jiaru Wang, Yaning Wang, Yu Wang, Renzhi Wang, Feng Feng, Wenbin Ma,